FYB.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:36):

Stats
Dagens volum	4 802.00
Gjennomsnittsvolum	8 148.00
Markedsverdi	705.39M
EPS	€0 ( 2024-04-25 )
Neste inntjeningsdato	( €0 ) 2024-05-28
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-10.57
ATR14	€0.0780 (0.20%)

Formycon AG Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Formycon AG Økonomi

Annual	2022
Omsetning:	€42.50M
Bruttogevinst:	€12.07M (28.41 %)
EPS:	€2.62

FY	2022
Omsetning:	€42.50M
Bruttogevinst:	€12.07M (28.41 %)
EPS:	€2.62

FY	2021
Omsetning:	€36.97M
Bruttogevinst:	€1.01M (2.72 %)
EPS:	€-1.225

FY	2020
Omsetning:	€34.23M
Bruttogevinst:	€8.76M (25.60 %)
EPS:	€-0.539

Financial Reports:

No articles found.

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.